Discovery and Optimization of Selective Nav1.8 Modulator Series That Demonstrate Efficacy in Preclinical Models of Pain-Reference-Cited by-同舟云学术

Discovery and Optimization of Selective Nav1.8 Modulator Series That Demonstrate Efficacy in Preclinical Models of Pain

Published:2015-05-11 Issue:6 Volume:6 Page:650-654
ISSN:1948-5875
Container-title:ACS Medicinal Chemistry Letters
language:en
Short-container-title:ACS Med. Chem. Lett.

Author:

Bagal Sharan K.¹,Bungay Peter J.²,Denton Stephen M.³,Gibson Karl R.³,Glossop Melanie S.³,Hay Tanya L.³,Kemp Mark I.³,Lane Charlotte A. L.³,Lewis Mark L.³,Maw Graham N.³,Million William A.³,Payne C. Elizabeth²,Poinsard Cedric³,Rawson David J.³,Stammen Blanda L.³,Stevens Edward B.²,Thompson Lisa R.³

Affiliation:

1. Worldwide Medicinal Chemistry, Pfizer Neusentis, The Portway Building, Granta Park, Great Abington, Cambridge CB21 6GS, U.K.

2. Neusentis U.K., Pfizer Global R&D, The Portway Building, Granta Park, Cambridge CB21 6GS, U.K.

3. Worldwide Medicinal Chemistry, Pfizer Global R&D, Sandwich CT13 9NJ, U.K.

Publisher

American Chemical Society (ACS)

Subject

Organic Chemistry,Drug Discovery,Biochemistry

Link

https://pubs.acs.org/doi/pdf/10.1021/acsmedchemlett.5b00059

Reference22 articles.

1. Altered Sodium Channel Gating as Molecular Basis for Pain: Contribution of Activation, Inactivation, and Resurgent Currents